ProKidney Stock Price, News & Analysis (NASDAQ:PROK) $1.83 +0.02 (+1.05%) (As of 02:42 PM ET) Add Compare Share Share Today's Range$1.71▼$1.8950-Day Range$1.21▼$4.7652-Week Range$1.12▼$14.19Volume284,402 shsAverage Volume460,843 shsMarket Capitalization$430.61 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media ProKidney MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside747.0% Upside$15.50 Price TargetShort InterestBearish26.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$23.38 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.66) to ($0.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.44 out of 5 starsMedical Sector828th out of 960 stocksBiological Products, Except Diagnostic Industry118th out of 135 stocks 3.5 Analyst's Opinion Consensus RatingProKidney has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, ProKidney has a forecasted upside of 747.0% from its current price of $1.83.Amount of Analyst CoverageProKidney has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted26.65% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently increased by 6.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROK. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for PROK on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,379,021.00 in company stock.Percentage Held by Insiders44.99% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.94% of the stock of ProKidney is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProKidney are expected to decrease in the coming year, from ($0.66) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About ProKidney Stock (NASDAQ:PROK)ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More PROK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROK Stock News HeadlinesNovember 30, 2023 | bizjournals.comProKidney makes two changes to C-suite, terminating long-serving COO and promoting from within for chief business officerNovember 30, 2023 | finance.yahoo.comProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business OfficerDecember 8, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 21, 2023 | msn.comProKidney former 10% owner Chamath Palihapitiya discloses sale of over 7M sharesNovember 21, 2023 | finance.yahoo.comProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx ConferenceNovember 17, 2023 | finance.yahoo.comProKidney Corp. (NASDAQ:PROK) Q3 2023 Earnings Call TranscriptNovember 17, 2023 | finance.yahoo.comCompanies Like ProKidney (NASDAQ:PROK) Are In A Position To Invest In GrowthNovember 16, 2023 | finance.yahoo.comAfter Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)December 8, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 16, 2023 | markets.businessinsider.comProKidney’s Future Promising: REACT Trial Success and Strategic Enrollment Shift Boosts Buy RatingNovember 15, 2023 | msn.comProKidney pauses manufacturing after audit, company saysNovember 14, 2023 | msn.comProKidney GAAP EPS of -$0.18November 14, 2023 | finance.yahoo.comProKidney Reports Third Quarter Financial ResultsNovember 14, 2023 | finance.yahoo.comProKidney Corp (PROK) Reports Q3 Financial Results: Focus on Chronic Kidney Disease TrialsNovember 13, 2023 | finance.yahoo.comProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate UpdatesNovember 1, 2023 | benzinga.com10% Owner At This Health Care Company Sells $645K of StockOctober 30, 2023 | finance.yahoo.comProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023October 23, 2023 | bizjournals.comPower Player 2023: Tim Bertram, ProKidneyOctober 20, 2023 | benzinga.comProKidney 10% Owner Sold $1.21M In Company StockOctober 17, 2023 | finance.yahoo.comProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerOctober 16, 2023 | investorplace.comIs Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock?October 16, 2023 | msn.comProkidney says Palihapitiya Chamath sells ~486.9K sharesOctober 12, 2023 | finance.yahoo.comWhy Shares of ProKidney Were Dropping ThursdaySeptember 22, 2023 | benzinga.comProKidney 10% Owner Trades $9.30M In Company StockSeptember 13, 2023 | seekingalpha.comREACT Or Retreat: ProKidney's Phase 3 Focal PointSeptember 6, 2023 | finance.yahoo.comProKidney confirms it will expand HQ complex, add 50 jobs in Winston-SalemSeptember 5, 2023 | finance.yahoo.comProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare ConferenceSee More Headlines Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PROK CUSIPN/A CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$16.00 Low Stock Price Target$15.00 Potential Upside/Downside+756.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,030,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-7.44% Debt Debt-to-Equity RatioN/A Current Ratio19.36 Quick Ratio19.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($42.77) per share Price / Book-0.04Miscellaneous Outstanding Shares235,435,000Free Float129,513,000Market Cap$426.14 million OptionableNot Optionable Beta0.81 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Deepak Jain Ph.D. (Age 69)Chief Operating Officer Comp: $768.65kMr. Todd C. Girolamo Esq. (Age 58)J.D., M.B.A., Chief Legal Officer & Corporate Secretary Comp: $600.17kKey CompetitorsReplimune GroupNASDAQ:REPLFusion PharmaceuticalsNASDAQ:FUSNLexeo TherapeuticsNASDAQ:LXEOOrchard TherapeuticsNASDAQ:ORTXAllogene TherapeuticsNASDAQ:ALLOView All CompetitorsInsiders & InstitutionsChamath PalihapitiyaSold 7,256,367 sharesTotal: $9.51 M ($1.31/share)Chamath PalihapitiyaSold 258,400 sharesTotal: $307,496.00 ($1.19/share)Morgan StanleyBought 590,964 shares on 11/16/2023Ownership: 4.375%Tudor Investment Corp Et AlBought 30,727 shares on 11/16/2023Ownership: 0.013%Chamath PalihapitiyaSold 282,300 sharesTotal: $420,627.00 ($1.49/share)View All Insider TransactionsView All Institutional Transactions PROK Stock Analysis - Frequently Asked Questions Should I buy or sell ProKidney stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PROK shares. View PROK analyst ratings or view top-rated stocks. What is ProKidney's stock price target for 2024? 2 brokerages have issued 12-month target prices for ProKidney's shares. Their PROK share price targets range from $15.00 to $16.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 747.0% from the stock's current price. View analysts price targets for PROK or view top-rated stocks among Wall Street analysts. How have PROK shares performed in 2023? ProKidney's stock was trading at $6.86 at the beginning of 2023. Since then, PROK shares have decreased by 73.3% and is now trading at $1.83. View the best growth stocks for 2023 here. When is ProKidney's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our PROK earnings forecast. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02. What ETF holds ProKidney's stock ? ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio. Who are ProKidney's major shareholders? ProKidney's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Social Capital Group LLC (4.92%), Morgan Stanley (4.37%), Northern Trust Corp (0.16%), Charles Schwab Investment Management Inc. (0.11%), Bank of New York Mellon Corp (0.05%) and Rhumbline Advisers (0.03%). View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PROK) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.